Attached files
| file | filename |
|---|---|
| EX-10 - EXHIBIT 10.1 - INTERNATIONAL ISOTOPES INC | exhibit101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 4, 2017
INTERNATIONAL ISOTOPES INC.
(Exact Name of Registrant as Specified in Charter)
| Texas | 0-22923 | 74-2763837 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 4137 Commerce Circle Idaho Falls, Idaho |
| 83401 |
| (Address of Principal Executive Offices) |
| (Zip Code) |
208-524-5300
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01.
Entry into a Material Definitive Agreement.
On May 4, 2017, International Isotopes Inc. (the “Company”) entered into a First Modification to Cobalt-60 Pellet Supply Agreement (the “Amendment”) with Nordion (Canada) Inc., as general partner of and on behalf of Nordion Sterilization LP (“Nordion”), pursuant to which the Cobalt-60 Pellet Supply Agreement, dated April 7, 2015, between the Company and Nordion (the “Agreement”) was amended to, among other things, reduce the amount of cobalt-60 pellets to be supplied under the Agreement and modify certain pricing terms, commitment fees and progress payments to be made under the Agreement. The Amendment also modified the Agreement to permit Nordion to terminate the Agreement if certain amounts of cobalt-60 pellets are not supplied by the Company under the Agreement over a two year period.
The foregoing description of the Amendment does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the document, which is attached hereto as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
| Description |
|
|
|
|
| 10.1† |
| First Modification to Cobalt-60 Pellet Supply Agreement, effective April 21, 2017, between International Isotopes Inc. and Nordion (Canada) Inc., as general partner of and on behalf of Nordion Sterilization LP. |
†
Certain portions of the exhibit have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 10, 2017 | International Isotopes Inc. |
| |
|
|
|
|
|
|
| By: | /s/ Steve T. Laflin |
|
|
|
| Steve T. Laflin President and Chief Executive Officer |
|
EXHIBIT INDEX
| Exhibit No. |
| Description |
|
|
|
|
| 10.1† |
| First Modification to Cobalt-60 Pellet Supply Agreement, effective April 21, 2017, between International Isotopes Inc. and Nordion (Canada) Inc., as general partner of and on behalf of Nordion Sterilization LP. |
†
Certain portions of the exhibit have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.